BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.
Also called NCT07946107
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Braveheart Bio, Inc.
- Registry
-
NCT07946107 -
2026-527471-29-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07946107. Randomized; quadruple masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Acronym
- NOBLEHEART-HCM
- Condition
- Cardiomyopathy, Hypertrophic Non-Obstructive
- Intervention (Drug)
- BHB-1893
- Intervention (Other)
- Placebo
- Lead sponsor
- Braveheart Bio, Inc.
Record details
- Record id
cardio:ct-nct07946107- Content hash
7bc647fdfd48e9063b81c5f514f83e74c0be2a5ff793cf9754781599dd161043